Pharmacotherapy for treatment-resistant schizophrenia

Meghan E Mcilwain1,2, Jeff Harrison1, Amanda J Wheeler1,3, Bruce R Russell1,21School of Pharmacy, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand; 2Centre for Brain Research, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand;...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Meghan E Mcilwain, Jeff Harrison, Amanda J Wheeler, et al
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/36b5e466ed7f4db5b9ccd890eec48990
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:36b5e466ed7f4db5b9ccd890eec48990
record_format	dspace
spelling	oai:doaj.org-article:36b5e466ed7f4db5b9ccd890eec489902021-12-02T00:17:44ZPharmacotherapy for treatment-resistant schizophrenia1176-63281178-2021https://doaj.org/article/36b5e466ed7f4db5b9ccd890eec489902011-03-01T00:00:00Zhttp://www.dovepress.com/pharmacotherapy-for-treatment-resistant-schizophrenia-a6747https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Meghan E Mcilwain1,2, Jeff Harrison1, Amanda J Wheeler1,3, Bruce R Russell1,21School of Pharmacy, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand; 2Centre for Brain Research, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand; 3School of Human Services, Griffith University, Queensland, AustraliaAbstract: Schizophrenia is a disabling mental illness with a lifetime prevalence of 0.7% worldwide and significant, often devastating, consequences on social and occupational functioning. A range of antipsychotic medications are available; however, suboptimal therapeutic response in terms of psychotic symptoms is common and affects up to one-third of people with schizophrenia. Negative symptoms are generally less amenable to treatment. Because of the consequences of inadequate symptom control, effective treatment strategies are required for people with treatment-resistant schizophrenia. Clozapine has been shown to be more effective than other antipsychotics in treatment-resistant populations in several studies; however, the occurrence of adverse effects, some of which are potentially life-threatening, are important limitations. In addition to those who are intolerant to clozapine, only 30% to 50% experience clinically significant symptom improvement. This review describes the recent evidence for treatment strategies for people not responding to nonclozapine antipsychotic agents and people not responding or only partially responding to clozapine.Keywords: antipsychotic, refractory, clozapine Meghan E McilwainJeff HarrisonAmanda J Wheeleret alDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2011, Iss default, Pp 135-149 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Meghan E Mcilwain Jeff Harrison Amanda J Wheeler et al Pharmacotherapy for treatment-resistant schizophrenia
description	Meghan E Mcilwain1,2, Jeff Harrison1, Amanda J Wheeler1,3, Bruce R Russell1,21School of Pharmacy, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand; 2Centre for Brain Research, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand; 3School of Human Services, Griffith University, Queensland, AustraliaAbstract: Schizophrenia is a disabling mental illness with a lifetime prevalence of 0.7% worldwide and significant, often devastating, consequences on social and occupational functioning. A range of antipsychotic medications are available; however, suboptimal therapeutic response in terms of psychotic symptoms is common and affects up to one-third of people with schizophrenia. Negative symptoms are generally less amenable to treatment. Because of the consequences of inadequate symptom control, effective treatment strategies are required for people with treatment-resistant schizophrenia. Clozapine has been shown to be more effective than other antipsychotics in treatment-resistant populations in several studies; however, the occurrence of adverse effects, some of which are potentially life-threatening, are important limitations. In addition to those who are intolerant to clozapine, only 30% to 50% experience clinically significant symptom improvement. This review describes the recent evidence for treatment strategies for people not responding to nonclozapine antipsychotic agents and people not responding or only partially responding to clozapine.Keywords: antipsychotic, refractory, clozapine
format	article
author	Meghan E Mcilwain Jeff Harrison Amanda J Wheeler et al
author_facet	Meghan E Mcilwain Jeff Harrison Amanda J Wheeler et al
author_sort	Meghan E Mcilwain
title	Pharmacotherapy for treatment-resistant schizophrenia
title_short	Pharmacotherapy for treatment-resistant schizophrenia
title_full	Pharmacotherapy for treatment-resistant schizophrenia
title_fullStr	Pharmacotherapy for treatment-resistant schizophrenia
title_full_unstemmed	Pharmacotherapy for treatment-resistant schizophrenia
title_sort	pharmacotherapy for treatment-resistant schizophrenia
publisher	Dove Medical Press
publishDate	2011
url	https://doaj.org/article/36b5e466ed7f4db5b9ccd890eec48990
work_keys_str_mv	AT meghanemcilwain pharmacotherapyfortreatmentresistantschizophrenia AT jeffharrison pharmacotherapyfortreatmentresistantschizophrenia AT amandajwheeler pharmacotherapyfortreatmentresistantschizophrenia AT etal pharmacotherapyfortreatmentresistantschizophrenia
_version_	1718403793128783872

Pharmacotherapy for treatment-resistant schizophrenia

Ejemplares similares